Seven-year exclusivity and beyond for drugs of rare diseases in China.

Jiang, Yale; Huang, Huiyao; Zhao, Guo; Ma, Peiwen; Zhang, Liang; Wang, Shuhang; Li, Ning

Jiang, Yale; Huang, Huiyao; Zhao, Guo; Ma, Peiwen; Zhang, Liang; Wang, Shuhang; Li, Ning.

Afiliación

Jiang Y; Clinical Trial Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Huang H; Clinical Trial Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Zhao G; Clinical Trial Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Ma P; Clinical Trial Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Zhang L; Zhejiang University, Hangzhou, Zhejiang, China.
Wang S; Clinical Trial Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Li N; Clinical Trial Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

Front Pharmacol ; 14: 1223056, 2023.

Article en En | MEDLINE | ID: mdl-37900168

Palabras clave

China; drug marketing application; drug policies; policy; rare disesases

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Front Pharmacol Año: 2023 Tipo del documento: Article País de afiliación: China

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google